摘要
目的观察静脉铁和口服铁在治疗肾性贫血中的疗效和安全性。方法50例血液透析患者随机分为两组:静脉组给予静脉铁(蔗糖铁)100 mg/次,每周2次。口服组给予口服铁(硫酸亚铁)300 mg/天。观察治疗后4周、8周、12周血红蛋白(Hb)、红细胞压积(Hct)、铁蛋白(SF)和转铁蛋白饱和度(TSAT)等的变化,并观察治疗达标后促红细胞生成素(EPO)维持量及不良反应发生情况。结果静脉组较口服组Hb、Hct、SF、TSAT上升速度快,疗效肯定,不良反应发生率低,治疗达标后EPO维持量减少。结论口服铁治疗贫血效果差,不能达到纠正贫血的理想目标,且不良反应相对多,蔗糖铁治疗肾性贫血疗效肯定,不良反应发生率低,可作为血液透析患者的长期补铁方案。
Objective To determine the efficacy and safety of intravenous iron sucrose with oral ferrous succinate in renal anemia patients. Methods 50 hemodialysis patients were randomized into two groups： Intravenous iron group（IV group） with 100 mg iron sucrose,twice a week and Oral iron group（Oral group） with 300 mg ferrous succinate every day.The changes in hemoglobin（Hb）,hematocrit（Hct）,serum ferritin（SF）,and transferrin saturation（TSAT） were assessed on week 4,8,and 12 after treatment.The maintenance dosages of erythropoietin（EPO） after reaching treatment target and the adverse events were also observed. Result There is higher increase of Hb,Hct,SF,and TSAT in IV group compared with Oral group.The adverse events and maintenance dosages of EPO is lower in IV group. Conclusion Oral iron which has more adverse events has poor efficacy in curing anemia that cannot correct anemia ideally.Meanwhile iron sucrose has positive effects on renal anemia with low adverse events,and it can be used as a long term iron supplementation in hemodialysis patients.
出处
《南华大学学报（医学版）》
2008年第5期640-642,共3页
Journal of Nanhua University(Medical Edition)
